Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03544047
Recruitment Status : Recruiting
First Posted : June 1, 2018
Last Update Posted : December 11, 2018
Sponsor:
Information provided by (Responsible Party):
Fei Ma, Peking Union Medical College

Brief Summary:
This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 2 years. The purpose of this study is to evaluate the consistency and accuracy of Patient-Derived Organoid Model of breast cancer to predict the clinical efficacy of the drug, as well as the possibility of guiding the neoadjuvant chemotherapy.

Condition or disease Intervention/treatment Phase
Organoid Drug: Paclitaxel Not Applicable

Detailed Description:

After obtaining informed consent, patients who met the eligibility criteria underwent biopsy of the primary lesion or metastatic lesion (such as lymph node).Under the premise of ensuring normal detection requirements, a certain volume of fresh tumor tissues will be retained and used for the cultivation of Patient-Derived Organoid Model.If the organoid cultivation is not successful, the corresponding follow-up observation will be stopped.If the organoid cultivation is successful, drug sensitivity verification or prediction by Patient-Derived Organoid Model will be completed (final report will be available in about one month). During this period, the patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen) and Herceptin was treated in HER2 amplification patients. After 3 cycles, the efficacy was assessed according to the RECIST solid tumor evaluation standard (version 1.1), and the evaluation methods mainly included physical examination, ultrasound, CT and MRI.If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks) and Herceptin was treated in HER2 amplification patients.If the evaluation of the curative effect is SD or PD, according to the result of drug sensitivity of the class organ, combined with the clinical practice, the doctor chooses the most sensitive treatment plan, and continues the 2 cycle treatment (6 weeks).After the completion of the evaluation, combined with the clinical situation, the next step is decided.For those who meet the conditions of the operation, the modified radical mastectomy or breast conserving surgery was performed after the neoadjuvant chemotherapy. The pCR status of the primary breast cancer and the axillary lymph nodes were evaluated after the operation. The adjuvant radiotherapy and endocrine therapy were given after the operation, and the long-term survival was observed.

Drug sensitivity tests include single drug and drug combination. The organs that are successfully cultured will be kept in liquid nitrogen for a specific time.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model
Estimated Study Start Date : January 1, 2019
Estimated Primary Completion Date : July 1, 2020
Estimated Study Completion Date : July 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy
Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: Experimental arm
Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen) and Herceptin was treated in HER2 amplification patients. After 3 cycles. If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks) and Herceptin was treated in HER2 amplification patients. If the evaluation of the curative effect is SD or PD, according to the result of drug sensitivity of the class organ, combined with the clinical practice, the doctor chooses the most sensitive treatment plan, and continues the 2 cycle treatment (6 weeks).
Drug: Paclitaxel
Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen). If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks).




Primary Outcome Measures :
  1. Overall Response rates (ORR) [ Time Frame: up to 36 months ]
    Defined as complete response (CR) + partial response (PR), assessed based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria.


Secondary Outcome Measures :
  1. Surgical excision rate [ Time Frame: up to 36 months ]
    After neoadjuvant chemotherapy, the ratio of patients who achieved surgical resection.

  2. Pathologic complete respons (pCR) rate [ Time Frame: up to 36 months ]
    pCR is defined as no infiltrating tumor cells in pathological examination in the primary breast and axillary lymph nodes.

  3. Disease-free survival (DFS) [ Time Frame: up to 36 months ]
    The period after curative treatment when no disease can be detected)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The age is more than 18 years old;
  • Pathology and immunohistochemical diagnosis of stage II-III breast cancer patients;
  • No prior treatment (such as anti-tumor therapy, immunotherapy, related surgery, etc.) may affect the outcome of the treatment;
  • According to the RECIST standard, the lesion was measured (the diameter of the primary lesion was greater than 1.0cm or the short diameter of the lymph node was greater than 1.5cm);
  • Metastatic lesions or primary lesions can obtain surgical tissue or adequate biopsy tissue;
  • No clinical diagnosis of other malignancies, unstable complications or uncontrolled infection;
  • ECOG PS score: 0-2 points;
  • Life expectancy is greater than 6 month;
  • The main organ function is normal;
  • The subjects volunteered to participate in this study, signed informed consent, followed up with good compliance.

Exclusion Criteria:

  • Unable to obtain sufficient tumor organizer by operation or biopsy;
  • Pregnant and lactating patients;
  • Patients with peripheral nervous system disorder caused by disease or have significant mental disorders and history of central nervous system disorders;
  • Patients with severe infections or active digestive tract ulcers need to be treated;
  • Allergic to chemotherapy drugs or surgical contraindication;
  • History of other malignant tumors;
  • Severe liver disease (such as cirrhosis), cardiovascular disease, kidney disease, respiratory disease, blood system disease, or uncontrolled diabetes;
  • Participating in or participating in other clinical trials within a month.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03544047


Contacts
Layout table for location contacts
Contact: Fei Ma, Professor 8610-87787652 drmafei@126.com

Locations
Layout table for location information
China
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Recruiting
Beijing, China
Contact: Binliang Liu, Postgraduate student    +8618211125199    liubinliang_onco@163.com   
Sponsors and Collaborators
Peking Union Medical College

Layout table for additonal information
Responsible Party: Fei Ma, Professor, Peking Union Medical College
ClinicalTrials.gov Identifier: NCT03544047     History of Changes
Other Study ID Numbers: NCC201804007
First Posted: June 1, 2018    Key Record Dates
Last Update Posted: December 11, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypersensitivity
Immune System Diseases
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action